Purpose. The occurrence of carbapenem-and colistin-resistance among Gram-negative bacteria is increasing worldwide. The aim of this study was to understand the distribution of carbapenem-and colistin-resistance in two areas in Tamil Nadu, India.
INTRODUCTION
Antibiotic resistance has become one of the increasing concerns in Gram-negative bacteria because of the lack of available treatment options. The adverse outcome of developing multidrug-resistant (MDR) bacterial infections can lead to up to a two-fold increase in severity compared to the same infections caused by susceptible strains [1] . Carbapenems are broad-spectrum antimicrobial agents that are very useful against infections caused by MDR Enterobacteriaceae [2] .
They are drugs of choice against infections caused by extended-spectrum beta-lactamase (ESBL)-producing Gramnegative bacteria [3] . From the healthcare epidemiological point of view, developing resistance towards carbapenems (imipenem, meropenem, doripenem and ertapenem) is of particular importance because carbapenems are last resort antibiotics [4] . The emergence of resistant bacteria against most classes of commercially available antibiotics and the shortage in discovery of new antibiotics that have activity against Gram-negative bacteria had led to the use of polymyxins as a valuable therapeutic option [5] . Finding treatment options against infections caused by carbapenem-resistant Gram-negative bacteria (CR-GNB) is one of the current challenges of our time resulting from an uncontrolled and irrational use of carbapenems [6] . Gram-negative bacteria have developed various resistance mechanisms such as the production of carbapenemase enzymes including b-lactamases (NDM, IMP, VIM, OXA, DIM, SIM) [7, 8] . The therapeutic armamentarium against infections caused by CR-GNB has limited the choice of antibiotics [9] . Colistin is a member of the polymyxin group polypeptide antibiotics with a significant activity against Gram-negative bacteria and it targets lipopolysaccharide in the outer membrane, although the exact mechanism of bacterial killing is still unknown [10] . The paucity of new antibiotics for a decade has allowed clinicians to reconsider colistin as an alternative therapeutic option against infections caused by Gram-negative bacteria [11] . The unconstrained use of colistin has caused the emergence of resistance in recent times [12] [13] [14] [15] .
Recently, the plasmid-mediated colistin resistant gene mcr-1 was identified, and modification of lipid A by MCR-1 and MCR-2 was reported [16] [17] [18] . There are different mechanisms involved in the spread of antibiotic resistance, such as the acquisition of genetic elements like plasmids, integrons, resistant islands and transposons [19] . Integrons (class I integrons) are known to play a significant role in the dissemination of antibiotic resistance genes within and in between bacterial species [20] [21] [22] . For these reasons, combination therapy with different classes of antibiotics is recommended to improve efficacy and also to prevent the emergence of further resistance [23] . In this study, we investigated the mechanism of carbapenem and colistin resistance in Gram-negative bacteria isolated from a clinical setting in Tamil Nadu, India, evaluated the dissemination of integrons, and assessed whether meropenem-colistin had a synergistic effect on the clinical strains.
METHODS

Isolate collection and identification
The clinical isolates used in this study were collected from two regions, Chennai and Tiruchirappalli (separated by 300 km) in Tamil Nadu, India. A total of 89 non-duplicate, Gram-negative, clinical isolates were collected from two diagnostic laboratories during August 2014 to March 2015. The samples from which isolates were cultured included urine, blood, pus, sputum, bronical aspirate, wound swab and cerebrospinal fluid. The isolates were received in vials from the clinical diagnostic centres and further processing was carried out in the Antibiotic Resistance Laboratory at VIT University, Vellore, India. The isolates were sub-cultured onto MacConkey agar (Hi-Media) and stored at À80 C for further analysis. Identification was done using phenotypic methods and based on the colony morphology and biochemical characteristics, and was confirmed by the VITEK identification system (bioM erieux).
Antibiotic susceptibility test
The MIC of meropenem was determined by agar dilution method following the Clinical and Laboratory Standards Institute (CLSI) guidelines. Briefly, Mueller-Hinton (MH) agar was prepared and the final concentrations of meropenem ranging from 0.06 to 128 mg l À1 were added to MH agar (Hi-Media) in Petri plates, mixed well and allowed to solidify. Then, bacterial inoculum grown overnight was diluted in saline (10 µl in 4.99 ml) and placed on the surface of the agar (1 µl) within the marked grids placed under the plates. The inoculum was allowed to dry and was then incubated at 37 C for 20 h. The lowest concentration of meropenem with the absence of visible bacterial growth was accepted as the MIC. The results were interpreted using the CLSI guidelines [24] .
The MIC of ertapenem was determined by the Epsilometer test (E-test). Briefly, MH agar plates were prepared and bacterial inocula adjusted to 0.5 McFarland turbidity standards were swabbed on the surface of the agar. Plates were dried for 5 min and Ertapenem Ezy MIC strips (Hi-Media) were placed in the centre of the plate and incubated at 37 C for 20 h. E-test strips were labelled from 0.002 to 32 mg l À1 and the MIC was determined. The results were interpreted using the CLSI guidelines.
For colistin, the MIC was determined using the micro-broth dilution method [24. Briefly, cation-adjusted MH broth (HiMedia) was prepared and 100 µl was disbursed in a 96-well microtitre plate. Colistin was added at final concentrations ranging from 0.06 to 128 mg l À1 in row 1 to 12 with row 12 being used as a growth control. Then, bacterial inocula of 5Â10 5 dilutions (CLSI guidelines) from overnight-grown cells were added to the respective wells and incubated at 37 C for 20 h. The results were interpreted using the CLSI guidelines.
Identification of carbapenemase producer
The modified Hodge test (MHT) and the EDTA inhibition tests were performed for the detection of carbapenemase production as previously described [25] . The interpretation was done according to CLSI guidelines.
For the EDTA inhibition test, a liquid culture was adjusted to a turbidity of 0.5 McFarland standard and spread on the surface of an MHA plate. Two 10 µg meropenem disks were placed 15 mm apart, and 10 µl of 0.5M EDTA (Hi-Media) was added to one of the disks (final EDTA concentration was 750 µg). Plates were incubated at 37 C for 20 h, and metallo-beta-lactamase (MBL) production was identified by any increase in zone diameter of >5 mm in the disk potentiated with EDTA. An MBL producer was defined as an isolate displaying reduced susceptibility to meropenem and tested positive in both the MHT and EDTA inhibition test.
Synergy testing
Time-kill analysis was performed for the isolates that were resistant to meropenem and colistin (27/89), and was based on the previously described method [26] . Antibiotics were used at final concentrations of 4 mg l À1 for colistin and 8 mg l À1 for meropenem with an aim to mimic the clinical serum peak levels during standard treatments. Briefly, flasks containing MH broth with meropenem and colistin (MER-COL) were inoculated with a test organism of approximately 10 5 c.f.u. ml À1 and incubated at 37 C in a shaking incubator. After the post-incubation period of 24 h, 100 µl aliquots were removed from the flask and serial dilutions were plated onto MH agar plates for determination of viable counts. After incubation for 24 h, colonies were counted to determine the synergistic effect of drugs in combination. Synergy was defined as any !2 log 10 decrease in colony count after 24 h compared with the same drug alone and remaining as synergy not detected (SND).
DNA extraction DNA extraction was done by the boiling preparation method. Briefly, overnight-grown bacteria were centrifuged at 9 000 Â g for 10 min, and to the harvested bacterial cells, 100 µl sterile distilled water was added and the cells were heated at 95 C for 10-15 min. The mixture was centrifuged at 5000 r.p.m. for 2 min and the supernatant was extracted and used as a source of template.
Screening of antibiotic resistance gene determinants
The presence of beta-lactamase genes bla NDM-1 , bla OXA-48-like , bla IMP , bla VIM and bla KPC were studied by multiplex PCR using specific primers and reaction conditions as described by Doyle et al. [27] . The integrase genes intI1, intI2 and intI3 and its internal gene cassettes were amplified by multiplex PCR using specific primers and reaction conditions described by Kargar et al. [28] . For the amplification of class 1 integrons, two primer sets were used: IntI1-F and IntI1-R for the intI1 gene, and 5¢-CS and 3¢-CS for the integron variable region as described by Kargar et al. [28] . For class 2 integrons, primers IntI2-F and IntI2-R were used for the intI2 gene, and primers attI2-F and orfX-R for characterization of gene cassette arrays. Integrase gene products were sequenced for further determination of the integron gene cassette.
Primers for the mcr-1 and mcr-2 genes were as described earlier [14, 18] . For identification of clonality between the bacterial species enterobacterial repetitive intergenic consensus (ERIC)-PCR was performed using ERIC2 primers as described by Versalovic et al. [29] .
Plasmid profiling and gene transferability assay Plasmid DNA was isolated for the resistant isolates harbouring resistance genes using the HiPurA plasmid DNA miniprep purification kit (Hi-Media) following the manufacturer's protocol, and the lambda DNA/EcoRI+HindIII marker (ThermoFisher Scientific) was used to identify the size of the plasmids. A total of 24 isolates carrying resistance genes encoding NDM-1 and OXA-48 were studied. In the case of intra-genus transfer of antibiotic resistance, only NDM-1-and OXA-48-encoded Escherichia coli isolates (11) were chosen and the selected isolates were also found to be colistin-resistant with a MIC of !32 mg l
showing sensitivity to all the antibiotics under study, was used as a recipient, while all the NDM-1-and OXA-48-encoded Escherichia coli served as the donors [30] . Donor and recipient cultures were grown overnight (10 8 cells ml
À1
) and 5 ml each bacterial culture was mixed (1 : 1) in a Luria-Bertani (LB) broth (Hi-Media) and was incubated without shaking for 16 h at 37
C. The transconjugants were selected on LB agar plates supplemented with streptomycin (100 µg ml
) in addition to either meropenem (10 µg ml À1 ) or colistin (10 µg ml
). In order to study the transfer of multiple resistance markers, combinations containing streptomycin with both meropenem and colistin were used, so a total of 10 Escherichia coli isolates resistant to both meropenem and colistin were studied. The transformants grown on the antibiotic plates were screened for resistance genes encoding NDM-1 and OXA-48 by PCR.
RESULTS
Identification of bacterial isolates
A total of 89 bacterial isolates identified as Gram-negative were included in this study. The identified clinical isolates included the following: 48 % (n=43) Escherichia coli, 20 % (n=18) Klebsiella pneumoniae, 11 % (n=10) Pseudomonas aeruginosa, 7 % (n=6) Enterobacter cloacae, 7 % (n=5) Acinetobacter baumannii, 4 % (n=4) Klebsiella oxytoca, 2 % (n=2) Proteus mirabilis and 1 % (n=1) Salmonella paratyphi. Of the 89 isolates, 81 % were found to be Enterobacteriaceae (Fig. 1 ).
Susceptibility to antibiotics
All the isolates received from clinical laboratories were found to be multiple-drug-resistant by the disk diffusion method at the clinical centres. Throughout this study, results were interpreted using the CLSI guidelines. Agar dilution MIC results showed that 58/89 (65 %) isolates were meropenem-resistant. The MIC 50 and MIC 90 values for meropenem agar dilution were 16 and 32 µg ml À1 , respectively. Among the different isolates, the percentage of Escherichia coli that were meropenem-resistant was 65 % (28/43), K. pneumoniae 67 % (12/18), Pseudomonas aeruginosa 60 % (6/10) and K. oxytoca 100 % (4/4). Meropenem resistance was also observed in isolates such as Enterobacter cloacae (3/6), A. baumannii (3/5), Proteus mirabilis (1/2) and S. paratyphi (1/1).
In the case of colistin, MIC results showed that 29 of 89 (33 %) isolates were resistant with MIC 50 of 1 µg ml À1 and MIC 90 of 16 µg ml
À1
. Colistin resistance was observed in isolates of Escherichia coli (61 %, 11/43), K. pneumoniae (33 %, 6/18) and Pseudomonas aeruginosa (30 %, 3/10). We also observed colistin resistance in Enterobacter cloacae (3/ 6), A. baumannii (2/5), K. oxytoca (2/4), Proteus mirabilis (1/2) and S. paratyphi (1/1), but since these numbers are small they do not reflect the real problem of resistance among these organisms. From the MIC results, it was found that 30 % (27/89) of the isolates used in this study were resistant to both meropenem and colistin (Fig. 1) .
Identification of carbapenemase producer
Using phenotypic tests, carbapenemase activity was detected in 52/89 (58.4 %) isolates by the MHT method and 50/89 (56.1 %) isolates by the EDTA inhibition test. A comparison of, disk diffusion and MIC results for meropenem showed 100 % and 65 % resistance, respectively (Table 1) . Overall, 50 (56 %) of the 89 tested clinical isolates were positive for the production of MBLs including carbapenemases.
Screening of antibiotic resistance genes
The presence of resistance genes bla NDM-1 , bla OXA-48-like , bla IMP , bla VIM , bla KPC and mcr-1 and mcr-2 was tested for all 89 isolates. PCR results showed that bla NDM-1 and bla OXA-48-like were the most predominant genes in carbapenem-resistant Gram-negative bacteria in our study. In total, 24/89 isolates carried resistant genes bla NDM-1 and bla OXA-48-like . Genes bla IMP , bla VIM and bla KPC were absent in all the isolates tested. Among bla NDM-1 (20/89) carriers were Escherichia coli (n=9), K. pneumoniae (n=4), Pseudomonas aeruginosa (n=3), K. oxytoca (n=3) and Enterobacter cloacae (n=1). Four bla OXA-48 producers were Escherichia coli (n=2), K. pneumoniae (n=1) and K. oxytoca (n=1). Interestingly, four of the Escherichia coli isolates (EC8, EC12, EC15 and EC33) were positive for bla NDM-1 and two Escherichia coli isolates (EC14 and EC22) carried bla OXA-48-like and were identified in plasmid DNA and studied further to determine if these genes were transferable. ERIC-PCR results showed that two of the carbapenem-resistant Escherichia coli (EC8 and EC15) carrying bla NDM-1 and two Escherichia coli (EC14 and EC22) carrying bla OXA-48-like had the same ERIC profile. Two of the bla NDM-1 Escherichia coli could not be grouped. None of the meropenem-susceptible isolates were positive for the tested carbapenem resistance genes and also none of the isolates carried more than one carbapenem resistance gene. Sequencing results showed that isolates positive for the bla NDM gene also had bla NDM-1 , and those positive for the bla OXA-48-like gene also had bla OXA-181 . In the case of colistin resistance, neither mcr-1 and mcr-2 were amplified in any of the isolates. Of the bla NDM-1 carriers, two Escherichia coli isolates (EC8 and EC10) and one bla OXA-181 -positive K. pneumoniae isolate (KP4) were found to be resistant to both meropenem and colistin.
Conjugation
Plasmid analysis revealed that the resistant isolates carried one or more plasmids ranging from 10 to 100 kb ( Table 2) . Conjugation studies were used to elucidate the intra-genus gene transfer of plasmid-borne resistance. The resistance was transferred to Escherichia coli AB1157. Out of nine Escherichia coli isolates carrying NDM, only four (EC8, EC12, EC15 and EC33) were found to transfer resistance plasmids to susceptible Escherichia coli AB1157. However, both Escherichia coli EC14 and EC22 -OXA carriers were able to transfer their plasmid-borne gene to susceptible Escherichia coli AB1157. The resistance was transferred at a frequency of 4-6Â10 À5 for both the transformants. No transformants were observed in the case of colistin. Additionally, multiple resistance transferability was studied using meropenem and colistin. In this case, 1/10 Escherichia coli isolate (with bla NDM-1 ) showed the simultaneous transfer of both markers at a low frequency of 3Â10
À6
.
Distribution of integrons in carbapenem-and colistin-resistant isolates
Of the 89 clinical isolates studied, 24 (26.9 %) were identified as positive for class 1 integrons, 20 (22.4 %) for class 2 integrons and three (3.3 %) for class 3 integrons (Table 3) . Sequencing results showed that the variable regions in class 1 integrons carried antibiotic-resistant genes and showed that one isolate had bla NDM-1 in its gene cassette (Fig. 2a, b) . Interestingly, 2/6 of the donor Escherichia coli (EC8 and EC10) involved in conjugation carried bla NDM-1 along with class 1 integrons, and the same was also amplified in transformants by PCR using specific primers, indicating the development of competence and uptake of DNA, leading to recombination and thus, transformation. Interestingly, in the Escherichia coli EC8 isolate, bla NDM-1 was found inside the class 1 integron (variable region) arrangement along with bla OXA-30 , which correlates with our earlier PCR studies, but the gene encoding OXA-30 was not amplified with specific primers in this study. However, dual resistance was found in Escherichia coli isolates producing plasmid-bound bla NDM-1 and also involved in co-transformation of dual resistance in the presence of class 1 integrons.
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Synergy testing
For synergy testing, isolates were chosen based on the DNA fingerprinting results obtained from ERIC-PCR. On observing ERIC results, five patterns of Escherichia coli, five patterns of K. pneumoniae, three patterns of Pseudomonas aeruginosa, two patterns of A. baumannii, two patterns of K. oxytoca, and one pattern each for Enterobacter cloacae, Proteus mirabilis and S. paratyphi were observed. A total of 20 isolates were included for the synergy testing; differences in colony count of !2 log 10 after 24 h exposure to the drugs in combination and as single agents was considered as synergy. The time-kill analysis showed synergy for 10/20 (50 %) isolates after 24 h (Table 4 ). Among the 10 synergetic isolates, 4/5 were Escherichia coli, 2/5 K. pneumoniae, and one each of Pseudomonas aeruginosa, K. oxytoca, Enterobacter cloacae and S. paratyphi. It was also noted that 4/10 synergetic isolates (two Escherichia coli, one K. pneumoniae and one Pseudomonas aeruginosa) were NDM-1 producers and 1/10 (K. pneumoniae) was an OXA-181 producer.
DISCUSSION
Our present study demonstrated that 65 % and 33 % of the Gram-negative bacteria under study were resistant to meropenem and colistin, respectively. The study simultaneously analysed the potential role of the plasmid-borne resistance in transferability and the type of integrons involved in the resistance of clinical Gram-negative isolates from Tamil Nadu, India. The molecular characteristics of integrons and plasmids in carbapenem-(NDM-and OXA-producing) and colistin-resistant Gram-negative clinical isolates were described to emphasize the rapid spread of resistance within clinical bacteria.
Many studies have demonstrated the wide spread of NDM-1-and OXA-48-like-producing carbapenem-resistant Gram-negative bacteria from India [31] [32] [33] . In addition, our previous studies also reported the distribution of *Plasmid sizes were identified using lambda DNA/EcoRI+HindIII marker. †Plasmids were absent in S. paratyphi and Proteus mirabilis.
bla NDM-1 , bla OXA-48-like and bla IMP among carbapenemresistant clinical isolates and also the distribution of colistin resistance among clinical isolates in Tamil Nadu [15, 34] . The rapid spread of carbapenem and colistin resistance among Gram-negative bacteria has become a major threat for the treatment of infectious diseases, not only in India, but also in other parts of the world. This study also showed the discrepancies among the results obtained by disk- 
diffusion, MIC, MHT and EDTA inhibition test for the detection of carbapenem resistance. Therefore the survey studies should not depend on a single identification strategy for reporting carbapenem resistance until adequate measures are established.
In recent years, there have been increasing reports of carbapenem and colistin resistance in Enterobacteriaceae harbouring both carbapenem-resistance and colistin-resistance genes in their plasmids [35] . Acquired resistance to colistin is extremely worrying considering that colistin is used as a lastresort antibiotic against carbapenem-resistant Gram-negative bacteria, especially Enterobacteriaceae [35] . Recently, plasmid-mediated carbapenem-and colistin-resistance in a clinical Escherichia coli isolate was reported in Switzerland [35, 36] . Enterobacter cloacae isolated from clinical samples were found to be resistant to both carbapenem and colistin in Colorado [37] . Colistin resistance in K. pneumoniae causing bacteraemia was reported from Tamil Nadu, India [38] , and the presence of the colistin-resistance mcr-1 gene was identified in Escherichia coli from the Indian subcontinent [39] .
Recently, identification of a plasmid-mediated mcr-1 gene conferring resistance to colistin in carbapenemase-producing Escherichia coli and K. pneumoniae from animals and patients in China and other parts of the world has been reported [40] . A recent study also found that the carbapenem-and colistin-resististant to both carbaant Escherichia coli producing plasmid-borne NDM-9 and MCR-1 was recovered from chicken meat samples in China [41] . Our present study showed the dissemination of carbapenem and colistin resistance (30 %) among Gram-negative clinical isolates including 78 % (21/27) in Enterobacteriaceae. The earlier studies also showed the co-transformation of plasmid-bound carbapenem and colistin resistance genes encoding NDM-9 and MCR-1 through conjugation [41] . In this study, we found that plasmid-borne carbapenem resistance genes bla NDM-1 and bla OXA-181 were transferred through intragenus gene transfer. The role of class 1 integrons in disseminating antibiotic resistance genes is well studied. A recent study characterized the carbapenem resistance gene bla VIM-2 inside the class 1 integron arrangement and reported the new integrons In1054 (intI1-aacA56-qacED1-sul1) and In1160 (intI1-aacA4-aacC1d-ISKpn4-gcuE-qacED1-sul1) in Pseudomonas aeruginosa [42] . Accordingly, our study characterized the bla NDM-1 and bla OXA-30 beta-lactamase genes inside the class 1 integron variable region (intI1-cmlA5-bla OXA-30 -bla NDM-1 -dhfrA17-ANT-3¢ the best of our knowle-aadA5-qacED1-sul1) and has been described in Escherichia coli for the first time, to the best of our knowledge. GenBank accession numbers of the class 1 integron sequences are: KX610373, KX660694, KX660695, KX660696 and KX685500.
As resistance plasmids are the major sources of antibiotic resistance transmission, these transferable elements conferring resistance to multiple antibiotics yield MDR bacteria. It is also possible that other mechanisms like integrons can co-transfer various plasmid-mediated resistance factors, accounting for the phenomenon of co-resistance as observed in our study. Plasmid-mediated transformation of resistance is of great concern and contributes to the spread of antibiotic resistance throughout bacterial species. Our study confirmed the plasmid-mediated transfer of carbapenem and colistin resistance and also contributed to the finding of bla NDM-1 inside class 1 integrons in plasmids. There are not many previous studies reporting the association of carbapenem resistance genes and class 1 integrons in plasmids. Our finding is a relatively low occurrence of class 1 integrons within carbapenem-and colistin-resistant clinical isolates, but demonstrating the transfer of this plasmid-mediated resistance is the important outcome of this study.
Combination therapy is preferred to overcome the multipledrug-resistant Gram-negative (MDR-GN) clinical pathogens. For carbapenem-and colistin-resistant isolates, combination therapy was used to improve the microbiological cure in critically-ill patients [43] . In earlier studies, broth-based methods were found to be accurate for assessing synergistic effects [44] . Colistin in combination with carbapenem is found to have synergistic effect against K. pneumoniae, Pseudomonas aeruginosa and A. baumannii [45] [46] [47] . Our in vitro combination therapy (meropenem +colistin) showed synergy in 50 % of the tested isolates which include bla NDM-1 and bla OXA-181 producers. Though there are no accepted standard procedures to perform synergy testing in routine microbiological laboratories, the recent clinical data show the positive effect of combination therapy to combat developing MDR pathogens.
Our study highlights the distribution of carbapenem-and colistin-resistant Gram-negative clinical pathogens harbouring plasmid-mediated resistance genes in Tamil Nadu, India. Additionally, we also identified the class 1 integron gene cassette regions harbouring antibiotic resistance genes. Our study also shows that plasmid-associated carbapenem resistance was transferable in some Escherichia coli strains harbouring the bla NDM-1 gene determinant and was associated with class 1 integrons. Our study demonstrated that carbapenem-resistant genes bla NDM-1 and bla OXA-181 coded for the most predominant enzymes in Gram-negative bacteria isolated from the Tamil Nadu region in India.
CONCLUSION
The distribution of antibiotic-resistant bacteria in clinical settings is worrying. Clinical pathogens, especially bacteria developing resistance to last-resort antibiotics such as carbapenem and colistin, are rapidly increasing because of horizontal gene transfer. Necessary steps are to be taken immediately to combat this serious healthcare problem in the hospital setting (nosocomial infections), and available alternative treatment options should be employed to overcome the problem. This study identifies that plasmids and integrons do play an important role in mobilization of resistance gene determinants. Plasmid-borne carbapenem resistance genes, NDM-1 and OXA-181 in Escherichia coli were found to be involved in horizontal gene transfer; hence proper surveillance and detection of resistance genes are essential to prevent their spread and diversification. We know that even if the core genome is stable, the accessory genome is more fluid and carbapenem resistance among Gram-negative pathogens has become common, usually by the acquisition of carbapenemase genes. Our study shows that the combination of meropenem and colistin can exert a synergistic effect against antibiotic-resistant Gram-negative bacteria, and with further clinical studies we can observe its improved therapeutic outcomes. Combination therapy has proven to be effective in the treatment of many cancers, viral infections and tuberculosis. To combat multiple-drugresistant Gram-negative bacterial infections, alternative approaches are urgently needed as the 'one drug-one target' model has limited viability, so combination therapy is indeed a novel way of tackling highly resistant bugs. In addition , combination therapy also has the potential to decrease the likelihood of resistance development. 
